FIGURE 2 | Priority reviews and orphan drugs.
From the following article:
2006 drug approvals: finding the niche
Joanna Owens
Nature Reviews Drug Discovery 6, 99-101 (February 2007)
doi:10.1038/nrd2247
2006 saw the FDA conducting fewer priority reviews than in 2004 and 2005 and slightly fewer drugs were given orphan designation. BLAs, biologic license application; NMEs, new molecular entities.
Download file
If the slide opens in your browser, select "File > Save As" to save it.